Can an app plus nicotine gum help hispanic smokers kick the habit?

NCT ID NCT06811038

First seen Nov 12, 2025 · Last updated Jun 19, 2026 · Updated 27 times

Summary

This phase III trial will enroll 854 Hispanic adults who smoke and want to quit. Participants will use the iCanQuit smartphone app, which teaches skills to manage cravings and prevent relapse. Half will also receive nicotine replacement therapy (gum, patch, or lozenge) to ease withdrawal. The study aims to see if adding NRT boosts quit rates compared to the app alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIGARETTE SMOKING-RELATED CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Nicotine replacement therapy (gum, patch, lozenge) and a smartphone app (iCanQuit)

What this could lead to

If successful, this could provide an effective, scalable smoking cessation program tailored for Hispanic adults, reducing smoking-related diseases.

What could go wrong

This is a large trial, but results depend on participants sticking with the app and NRT. The benefit may be modest, and long-term abstinence is hard to maintain.

Conditions

The condition(s) this trial relates to.

squamous cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.